---
title: "Jefferies Keeps Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292468535.md"
description: "Jefferies analyst James Vane maintained a Buy rating on Fresenius SE & Co. KGaA with a €55.00 price target. The broader analyst consensus for the company is a Strong Buy, with an average price target of €53.84. Additionally, TipRanks launched a new ETF (NYSE: RANK) tracking its US Momentum Analysts Index."
datetime: "2026-07-13T09:45:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292468535.md)
  - [en](https://longbridge.com/en/news/292468535.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292468535.md)
---

# Jefferies Keeps Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)

In a report released today, James Vane from Jefferies maintained a Buy rating on Fresenius SE & Co. KGaA, with a price target of €55.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Vane is ranked #10395 out of 12331 analysts.

Currently, the analyst consensus on Fresenius SE & Co. KGaA is a Strong Buy with an average price target of €53.84.

### Related Stocks

- [FRE.DE](https://longbridge.com/en/quote/FRE.DE.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [FSNUY.US](https://longbridge.com/en/quote/FSNUY.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Fresenius Kabi vedolizumab biosimilar PB016 accepted for FDA, EMA review](https://longbridge.com/en/news/294465104.md)
- [Deutsche Bank  Reaffirms Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)](https://longbridge.com/en/news/293183874.md)
- [Fresenius names Thomas Thestrup head of new Ventures unit](https://longbridge.com/en/news/293578816.md)
- [Fresenius establishes venture fund of more than €200 million to drive healthcare innovation | FSNUY Stock News](https://longbridge.com/en/news/293588612.md)
- [Jefferies Sticks to Its Buy Rating for EssilorLuxottica SA (0OMK)](https://longbridge.com/en/news/294105311.md)